Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review

Mattia Garutti; Gaia Griguolo; Andrea Botticelli; Giulia Buzzatti; Carmine De Angelis; Lorenzo Gerratana; Chiara Molinelli; Vincenzo Adamo; Giampaolo Bianchini; Laura Biganzoli; Giuseppe Curigliano; Michelino De Laurentiis; Alessandra Fabi; Antonio Frassoldati; Alessandra Gennari; Caterina Marchiò; Francesco Perrone; Giuseppe Viale; Claudio Zamagni; Alberto Zambelli; Lucia Del Mastro; Sabino De Placido; Valentina Guarneri; Paolo Marchetti; Fabio Puglisi

doi:10.3390/cancers14081898

Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review

Mattia Garutti, Gaia Griguolo, Andrea Botticelli, Giulia Buzzatti, Carmine De Angelis, Lorenzo Gerratana, Chiara Molinelli, Vincenzo Adamo, Giampaolo Bianchini, Laura Biganzoli, Giuseppe Curigliano, Michelino De Laurentiis, Alessandra Fabi, Antonio Frassoldati, Alessandra Gennari, Caterina Marchiò, Francesco Perrone, Giuseppe Viale, Claudio Zamagni, Alberto ZambelliLucia Del Mastro, Sabino De Placido, Valentina Guarneri, Paolo Marchetti, Fabio Puglisi

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo di review › peer review

Abstract

Breast cancer is one of the major causes of cancer-related morbidity and mortality in women worldwide. During the past three decades, several improvements in the adjuvant treatment of hormone receptor-positive/HER2−negative breast cancer have been achieved with the introduction of optimized adjuvant chemotherapy and endocrine treatment. However, estimating the risk of relapse of breast cancer on an individual basis is still challenging. The IRIDE (hIGh Risk DEfinition in breast cancer) working group was established with the aim of reviewing evidence from the literature to synthesize the current relevant features that predict hormonepositive/HER2−negative early breast cancer relapse. A panel of experts in breast cancer was involved in identifying clinical, pathological, morphological, and genetic factors. A RAND consensus method was used to define the relevance of each risk factor. Among the 21 features included, 12 were considered relevant risk factors for relapse. For each of these, we provided a consensus statement and relevant comments on the supporting scientific evidence. This work may guide clinicians in the practical management of hormone-positive/HER2−negative early breast cancers.

Lingua originale	Inglese
Numero di articolo	1898
Rivista	Cancers
Volume	14
Numero di pubblicazione	8
DOI	https://doi.org/10.3390/cancers14081898
Stato di pubblicazione	Pubblicato - 1 apr 2022

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.3390/cancers14081898

Altri file e collegamenti

Link to publication in Scopus

Cita questo

Garutti, M., Griguolo, G., Botticelli, A., Buzzatti, G., De Angelis, C., Gerratana, L., Molinelli, C., Adamo, V., Bianchini, G., Biganzoli, L., Curigliano, G., De Laurentiis, M., Fabi, A., Frassoldati, A., Gennari, A., Marchiò, C., Perrone, F., Viale, G., Zamagni, C., ... Puglisi, F. (2022). Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review. Cancers, 14(8), Articolo 1898. https://doi.org/10.3390/cancers14081898

@article{170777c8995a461b882778ee18d85647,

title = "Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review",

abstract = "Breast cancer is one of the major causes of cancer-related morbidity and mortality in women worldwide. During the past three decades, several improvements in the adjuvant treatment of hormone receptor-positive/HER2−negative breast cancer have been achieved with the introduction of optimized adjuvant chemotherapy and endocrine treatment. However, estimating the risk of relapse of breast cancer on an individual basis is still challenging. The IRIDE (hIGh Risk DEfinition in breast cancer) working group was established with the aim of reviewing evidence from the literature to synthesize the current relevant features that predict hormonepositive/HER2−negative early breast cancer relapse. A panel of experts in breast cancer was involved in identifying clinical, pathological, morphological, and genetic factors. A RAND consensus method was used to define the relevance of each risk factor. Among the 21 features included, 12 were considered relevant risk factors for relapse. For each of these, we provided a consensus statement and relevant comments on the supporting scientific evidence. This work may guide clinicians in the practical management of hormone-positive/HER2−negative early breast cancers.",

keywords = "TNM, adjuvant, breast cancer, chemotherapy, consensus, ctDNA, endocrine therapy, genomic signature, hormone receptors, risk of relapse",

author = "Mattia Garutti and Gaia Griguolo and Andrea Botticelli and Giulia Buzzatti and {De Angelis}, Carmine and Lorenzo Gerratana and Chiara Molinelli and Vincenzo Adamo and Giampaolo Bianchini and Laura Biganzoli and Giuseppe Curigliano and {De Laurentiis}, Michelino and Alessandra Fabi and Antonio Frassoldati and Alessandra Gennari and Caterina Marchi{\`o} and Francesco Perrone and Giuseppe Viale and Claudio Zamagni and Alberto Zambelli and {Del Mastro}, Lucia and {De Placido}, Sabino and Valentina Guarneri and Paolo Marchetti and Fabio Puglisi",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = apr,

day = "1",

doi = "10.3390/cancers14081898",

language = "English",

volume = "14",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "8",

}

Garutti, M, Griguolo, G, Botticelli, A, Buzzatti, G, De Angelis, C, Gerratana, L, Molinelli, C, Adamo, V, Bianchini, G, Biganzoli, L, Curigliano, G, De Laurentiis, M, Fabi, A, Frassoldati, A, Gennari, A, Marchiò, C, Perrone, F, Viale, G, Zamagni, C, Zambelli, A, Del Mastro, L, De Placido, S, Guarneri, V, Marchetti, P & Puglisi, F 2022, 'Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review', Cancers, vol. 14, n. 8, 1898. https://doi.org/10.3390/cancers14081898

TY - JOUR

T1 - Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer

T2 - A Consensus Review

AU - Garutti, Mattia

AU - Griguolo, Gaia

AU - Botticelli, Andrea

AU - Buzzatti, Giulia

AU - De Angelis, Carmine

AU - Gerratana, Lorenzo

AU - Molinelli, Chiara

AU - Adamo, Vincenzo

AU - Bianchini, Giampaolo

AU - Biganzoli, Laura

AU - Curigliano, Giuseppe

AU - De Laurentiis, Michelino

AU - Fabi, Alessandra

AU - Frassoldati, Antonio

AU - Gennari, Alessandra

AU - Marchiò, Caterina

AU - Perrone, Francesco

AU - Viale, Giuseppe

AU - Zamagni, Claudio

AU - Zambelli, Alberto

AU - Del Mastro, Lucia

AU - De Placido, Sabino

AU - Guarneri, Valentina

AU - Marchetti, Paolo

AU - Puglisi, Fabio

PY - 2022/4/1

Y1 - 2022/4/1

N2 - Breast cancer is one of the major causes of cancer-related morbidity and mortality in women worldwide. During the past three decades, several improvements in the adjuvant treatment of hormone receptor-positive/HER2−negative breast cancer have been achieved with the introduction of optimized adjuvant chemotherapy and endocrine treatment. However, estimating the risk of relapse of breast cancer on an individual basis is still challenging. The IRIDE (hIGh Risk DEfinition in breast cancer) working group was established with the aim of reviewing evidence from the literature to synthesize the current relevant features that predict hormonepositive/HER2−negative early breast cancer relapse. A panel of experts in breast cancer was involved in identifying clinical, pathological, morphological, and genetic factors. A RAND consensus method was used to define the relevance of each risk factor. Among the 21 features included, 12 were considered relevant risk factors for relapse. For each of these, we provided a consensus statement and relevant comments on the supporting scientific evidence. This work may guide clinicians in the practical management of hormone-positive/HER2−negative early breast cancers.

AB - Breast cancer is one of the major causes of cancer-related morbidity and mortality in women worldwide. During the past three decades, several improvements in the adjuvant treatment of hormone receptor-positive/HER2−negative breast cancer have been achieved with the introduction of optimized adjuvant chemotherapy and endocrine treatment. However, estimating the risk of relapse of breast cancer on an individual basis is still challenging. The IRIDE (hIGh Risk DEfinition in breast cancer) working group was established with the aim of reviewing evidence from the literature to synthesize the current relevant features that predict hormonepositive/HER2−negative early breast cancer relapse. A panel of experts in breast cancer was involved in identifying clinical, pathological, morphological, and genetic factors. A RAND consensus method was used to define the relevance of each risk factor. Among the 21 features included, 12 were considered relevant risk factors for relapse. For each of these, we provided a consensus statement and relevant comments on the supporting scientific evidence. This work may guide clinicians in the practical management of hormone-positive/HER2−negative early breast cancers.

KW - TNM

KW - adjuvant

KW - breast cancer

KW - chemotherapy

KW - consensus

KW - ctDNA

KW - endocrine therapy

KW - genomic signature

KW - hormone receptors

KW - risk of relapse

UR - http://www.scopus.com/inward/record.url?scp=85127791037&partnerID=8YFLogxK

U2 - 10.3390/cancers14081898

DO - 10.3390/cancers14081898

M3 - Review article

SN - 2072-6694

VL - 14

JO - Cancers

JF - Cancers

IS - 8

M1 - 1898

ER -

Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review

Abstract

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo